Solid Organ Transplant

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/147

encourage image

There's no tags or description

Looks like no tags are added yet.

148 Terms

1
New cards

prolong both pt and graft survival

What are the goals of transplantation?

2
New cards

more than 100,000

How many ppl are waiting on organ tranplants?

3
New cards

13

How many ppl die each day while awaiting organ transplants?

4
New cards

86%

What % of pts needs a transplant need a kidney?

5
New cards

up to 8 lives

How many lives can 1 donor save?

6
New cards

United Network for Organ Sharing (UNOS)

• Responsible for organ allocation in the US

• UNOS' computer system generates a ranked list of transplant candidates suitable to receive an organ when donor becomes available

7
New cards

Ranking factors vary by organ

• Medical urgency (heart/liver are prioritized if critically ill)

• Waiting time

• Organ size compatibility

• Distance between donor hospital and transplant center

• Biologic compatibility (blood type, tissue matching, etc.)

8
New cards

distance

Prioritization of candidates based on _________ from donor hospital

9
New cards

MELD (Model for End-Stage Liver Disease) Score

Organ Specific Scoring strongly influencing placement in the match for a liver

10
New cards

CAS (Composite Allocation Score)

Organ Specific Scoring strongly influencing placement in the match for a lung

11
New cards

Status 1-6 based on disease severity

Organ Specific Scoring strongly influencing placement in the match for a heart

12
New cards

KDPI (Kidney Donor Profile Index) and wait time

Organ Specific Scoring strongly influencing placement in the match for a kidney

13
New cards

US federal system for organ transplantation in the US

What is OPTN?

14
New cards

Organ Procurement and Transplantation Network

OPTN

15
New cards

OPTN

Coordinate organ donation and transplantation linking professionals, hospitals, and organizations to match donated organs with patients, increase organ availability, and ensure equitable allocation

16
New cards

transplant rejection

-Transplanting an organ/tissue from a donor into a recipient results in immune system activation leading to an attempt to destroy the transplanted organ

-often leads to graft damage and occasionally graft failures

17
New cards

Suppression of the immune system via lifelong medication

• Patient adherence is crucial

• Numerous medication side effects

How do we prevent rejection?

18
New cards

Allograft

-One individual to another

-Different genotype Same species (human to human)

19
New cards

Isograft

-genetically identical donor

-identical twin

20
New cards

autograft

-same patient

-one site to another (SCT)

21
New cards

xenograft

-between individuals

-different species (pig to human)

22
New cards

CMS (Center's for Medicare and Medicaid Services)

require a"pharmacology expert" typically a clinical transplant pharmacist to be part of the multidisciplinary team to meet accreditation standards and ensure patient safety and optimal medication management

23
New cards

Kidney indication for transplant

• ESRD due to hypertension and diabetes

• Glomerulonephritis

• Polycystic kidney disease

• Lupus

• Congenita

24
New cards

liver indications for transplant

• Metabolic dysfunction associated steatohepatitis (MASH)

• EtoH related cirrhosis

• Hepatitis B/C

• Hepatocellular carcinoma (HCC)

25
New cards

heart indications for transplant

• Cardiomyopathies

• Cardiovascular disease (CVD)

• Congenital

• Uncontrolled ventricular arrythmias

26
New cards

lung indications for transplant

• COPD

• Pulmonary fibrosis

• Cystic fibrosis

• Pulmonary hypertension

27
New cards

MHC

-allows T-cells to interact with antigen presenting cells (APCs)

-is expressed in all nucleated cells

-HLA in humans

28
New cards

HLA

encodes cell surface molecules which regulate the immune system

29
New cards

antibody formation

Exposure to non-self HLA leads to _________

30
New cards

immunologic risk

is defined by the presence of pre-formed antibodies to donor HLA

31
New cards

Panel Reactive Antibody (PRA)

amount of HLA antibody present in a potential recipient's serum

• Determined by testing the recipient serum to a panel of numerous types of HLA

• PRA >20% = sensitized; PRA >80% highly sensitized

32
New cards

Calculated PRA (cPRA)

represents the percentage of actual organ donors that express one or more unacceptable HLA antigens

• Includes HLA-A, -B, -DR, and -DQ

• Provides a meaningful estimate of transplantability

33
New cards

fewer

The higher the cPRA score the ______ compatible donors

34
New cards

10%

90% cPRA means possible match with _____ of the donor pool.

35
New cards

Crossmatching

pre-transplant immunologic screening test to detect donor specific antibodies (DSA) in the serum of the potential recipient

36
New cards

Positive crossmatch

recipient antibody activation to donor tissue

  • recipient has antibodies against donor tissue


37
New cards

Negative crossmatch

suitable donor → proceed to transplant

38
New cards

Donor Specific Antibody (DSA)

antibodies against donor antigens found within allograft vessels

• Preformed DSA or de novo DSA

39
New cards

Risk factors for de novo DSA

• High HLA mismatches (especially DQ mismatches)

• Inadequate immunosuppression and/or nonadherence

• Graft inflammation

40
New cards

DSA

High titers of _____ have been correlated with complement binding and more severe tissue injury

41
New cards

hyperacute reaction

What happens if a recipient who has type A blood receives a kidney from a type B donor?

42
New cards

ABO Incompatible Transplant

• Helps expand the donor pool

• Makes a historical barrier to transplant feasible

• Requires pre-transplant desensitization techniques

43
New cards

plasmapheresis (removal of antibodies) and immunosuppression (rituximab) which depletes b cells

What are the desensitization techniques used pre-transplantion in ABO incompatible pts?

44
New cards

A, O

Blood type A is compatible with:

45
New cards

B, O

Blood type B is compatible with:

46
New cards

A, B, AB, O

Blood type AB is compatible with:

47
New cards

O

Blood type O is compatible with:

48
New cards

increase risk of infection

-Lymphocyte depleting induction

-Donor derived infections

-Excess immune suppression

-Elderly

-Prior use of immunosuppressant

49
New cards

increase risk of rejection

-HLA mismatches

-Panel reactive antibody

-Pregnancy

-Blood transfusions

-Implantable devices

-Hemodialysis

-Prior transplant

50
New cards

minimize the risk of rejection but also balance the risk of infection

What is the goal of immunosuppression in SOT?

51
New cards

-induction immunosuppression

-maintenance immunosuppression

-treatment of rejection

What are the stages of immunosuppression in SOT?

52
New cards

Depleting induction

• Anti-thymocyte globulin (rATG) (Thymoglobulin®)

• Alemtuzumab (Campath®)

53
New cards

Non-depleting induction

• Basiliximab (Simulect®)

• Methylprednisolone

54
New cards

improves

Use of Induction Therapy ________ Graft Survival in Kidney Transplantation

55
New cards

Signal 1 of T cell activation

APC presents MHC Class II antigen to TH through the TCR-CD3 Complex

• Activates calcineurin pathway

• IL-2 is generated from the nucleus

56
New cards

signal 2 of t-cell activation

Co-stimulatory protein binding of CD80 and CD86 on theAPC to CD28 on the TH, initiating 3 signal transduction pathways

57
New cards

signal 3 of t cell activation

IL-2 is released and binds to IL-2 receptor on the T-cell, activating target of rapamycin necessary for cellular proliferation

58
New cards

activated proliferating T cell

Signal 1 + Signal 2 + Signal 3 equals:

59
New cards

Thymoglobulin

Available as Rabbit Antithymocyte Globulin (r-ATG; Thymoglobulin®)

• Used in SOT

60
New cards

Binds to various T cell markers leading to prolonged CD4 lymphocyte depletion

Rabbit Anti-Thymocyte Globulin(Thymoglobulin®, rATG) Mechanism of Action

61
New cards

V over 6 hours

• Give via central line; requires filter

• Risk of thrombophlebitis

• Can be given safely peripherally but not preferred

• Effects last 6-12 months

Admin of Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG):

62
New cards

Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG)

Adverse Effects

• Cytokine release syndrome and infusion site reactions

• Pre-medication is required

• acetaminophen/diphenhydramine/methylprednisolone 30 minutes prior to infusion

63
New cards

leukopenia and thrombocytopenia

What are the monitoring parameters of Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG)?

64
New cards

anaphylaxis (equine version- Atgam)

BBW for Rabbit Anti-Thymocyte Globulin (Thymoglobulin®, rATG):

65
New cards

Binds to CD52 on the surface of Tcells, B cells, monocytes, macrophages, NKcells, and a subpopulation of granulocytes

Alemtuzumab (Campath®) Mechanism of Action

66
New cards

IV; Peripheral orcentral

• Effects last 12+months

Admin of Alemtuzumab (Campath®):

67
New cards

AEs of Alemtuzumab (Campath®)

• Cytokine release syndrome

• Infusion site reactions

• Requires pre-medication

• Cytopenias

• Infections

68
New cards

Basiliximab (Simulect®)

-More commonly used if low risk for rejection or first line for liver transplantation

-decreased risk of infection vs depleting induction therapy

-effects lasts about 30 days

69
New cards

Chimeric (murine/human) monoclonal antibody that binds to and blocks the alpha chain of CD25 IL-2 receptor on activated T lymphocytes

Basiliximab (Simulect®) MOA

70
New cards

AEs of Basiliximab (Simulect®)

Non-specific (e.g., nausea, headache, hypertension)

71
New cards

Numerous; (i.e., decrease leukocyte accumulation, lymphocyte and complement function, cytokine release, etc.)

Methylprednisolone MOA

72
New cards

IV taper to oral; central or peripheral line

Methylprednisolone admin:

73
New cards

AEs of Methylprednisolone

• Hyperglycemia

• Peptic ulcers

• Leukocytosis

• Edema/weight gain

• Mood disturbances

• Insomnia

• Osteoporosis

74
New cards

Maintenance Immunosuppression

-pt specific factors are imp in determining this

-individualized based on the person and the transplant center

-no one size fits all approach

75
New cards

Calcineurin inhibitor + antimetabolite + steroid

Triple Maintenance Immunosuppression

76
New cards

Calcineurin Inhibitors

-Tacrolimus

-Cyclosporine

77
New cards

Capsule, granules for oral solution, injection

Tacrolimus (FK 506) formulations

78
New cards

Prograf®, Astagraf XL®(extended-release tacrolimus), Envarsus XR® (extended-release tacrolimus)

Tacrolimus brand names

79
New cards

Binds to FK binding protein -> complex binds to calcineurin -> blocks IL-2

Tacrolimus MOA

80
New cards

Individualized weight based dose to achieve goal trough levels

Tacrolimus dosing:

81
New cards

Prograf

All of the Tacrolimus formulations are QD except _______ is BID!

82
New cards

AEs of Tacrolimus

Hypomagnesemia, hypertension, hyperglycemia, neurotoxicity (headache, tremors, seizure, neuropathy), nephrotoxicity, new onset diabetes after transplant (NODAT), alopecia

83
New cards

1:4 or 1:5

Prograf IV to PO conversion:

84
New cards

2:1

Prograf PO to Sublingual conversion:

85
New cards

1:1

Astagraf to Prograf conversion:

86
New cards

1:0.8

Prograf to Envarsus XR

Astagraf to Envarsus XR

conversion is the same:

87
New cards

Increased risk of malignancy (lymphoma; skin cancer); increased risk of infection

BW with Tacrolimus:

88
New cards

Binds to cyclophilin -> complex binds to calcineurin -> blocks IL-2 production

Cyclosporine MOA

89
New cards

AEs of Cyclosporine

Hyperkalemia, hyperlipidemia, hyperglycemia, hypomagnesemia, gingival hyperplasia, hirsutism, neurotoxicity, hyperuricemia

90
New cards

Formulations of Cyclosporine

Capsule, oral solution, injection twice daily

Non-modified (Sandimmune®) vs. Modified (Neoral®/Gengraf®)

• Modified cyclosporine formulated for better absorption and bioavailability; microemulsion formula

• Not interchangeable

91
New cards

Increased risk of malignancy; increased risk of infection, nephrotoxicity (at anytrough level); hypertension

BW with Cyclosporine:

92
New cards

1:3

Cyclosporine IV to PO conversion:

93
New cards

Rifampin

Phenytoin

Carbamazepine

Phenobarbital

Isoniazid

St. Johns Wort

What are the CYP3A4 Inducers that decrease Calcineurin inhibitor drug levels:

94
New cards

Azole antifungals

Diltiazem

Verapamil

Erythromycin

Clarithromycin

Protease inhibitors

Grapefruit juice

Amiodarone

What are the CYP3A4 inhibitors that increase calcineurin inhibitor drug levels?

95
New cards

converted to active form mycophenolic acid; inhibits inosine monophosphate dehydrogenase which is responsible for de novo purine and DNA synthesis in T and B cells

Mycophenolate Mofetil(Cellcept®)Mycophenolic Acid (Myfortic®) MOA

96
New cards

formulations of Mycophenolate Mofetil(Cellcept®)Mycophenolic Acid (Myfortic®)

CellCept®- Tablet; capsule; suspension; injection; Myfortic® - delayed release tablet *Do not interchange without authorization*

97
New cards

250 mg CellCept= 180 mg Myfortic

Dosing conversion of Celll Cept to Myfortic

98
New cards

AEs of Mycophenolate Mofetil(Cellcept®)Mycophenolic Acid (Myfortic®)

Diarrhea, nausea, vomiting, leukopenia

99
New cards

pregnancy; mycophenolate REMS

CI with Mycophenolate Mofetil(Cellcept®) Mycophenolic Acid (Myfortic®):

100
New cards

Increased risk of malignancy (skin cancer; lymphoma); increased risk of infection, increased risk of congenital malformations and spontaneous abortions

BW of Mycophenolate Mofetil (Cellcept®) Mycophenolic Acid (Myfortic®):